A new JAMA analysis shows that the cost of PCSK9 inhibitors is significantly overpriced for the value they provide and prices would need to be reduced significantly in order for the drugs to meet acceptable cost-effectiveness thresholds.
Based on the new analysis the Campaign for Sustainable Rx Pricing’s (CSRxP) issued the following statement from Executive Director John Rother:
“For more than a year, CSRxP has been calling attention to outrageously priced PCSK9 inhibitors like Repatha and Praluent. The JAMA report is further proof that these high drug prices threaten the overall sustainability of our health care system. The dangerous trend of high-priced drugs has to be reversed and a common-sense solution like pricing medications according to their value and cost-effectiveness is one necessary step to fix the broken prescription drug market, but it must also be combined with increased transparency and competition.”